Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John D. Schreier is active.

Publication


Featured researches published by John D. Schreier.


Journal of Computer-aided Molecular Design | 2014

Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs

Georgia B. McGaughey; Christopher I. Bayly; Christopher D. Cox; John D. Schreier; Michael J. Breslin; Michael J. Bogusky; Steve Pitzenberger; Richard G. Ball; Paul J. Coleman

Dual Orexin Receptor Antagonists (DORA) bind to both the Orexin 1 and 2 receptors. High resolution crystal structures of the Orexin 1 and 2 receptors, both class A GPCRs, were not available at the time of this study, and thus, ligand-based analyses were invoked and successfully applied to the design of DORAs. Computational analysis, ligand based superposition, unbound small-molecule X-ray crystal structures and NMR analysis were utilized to understand the conformational preferences of key DORAs and excellent agreement between these orthogonal approaches was seen in the majority of compounds examined. The predominantly face-to-face (F2F) interaction observed between the distal aromatic rings was the core 3D shape motif in our design principle and was used in the development of compounds. A notable exception, however, was seen between computation and experiment for suvorexant where the molecule exhibits an extended conformation in the unbound small-molecule X-ray structure. Even taking into account solvation effects explicitly in our calculations, we nevertheless find support that the F2F conformation is the bioactive conformation. Using a dominant states approximation for the partition function, we made a comprehensive assessment of the free energies required to adopt both an extended and a F2F conformation of a number of DORAs. Interestingly, we find that only a F2F conformation is consistent with the activities reported.


Archive | 2009

2,5-disubstituted piperidine orexin receptor antagonists

Christopher D. Cox; Paul J. Coleman; Michael J. Breslin; Izzat T. Raheem; John D. Schreier; Anthony J. Roecker


Archive | 2008

Pyridyl piperidine orexin receptor antagonists

Michael J. Breslin; Paul J. Coleman; Christopher D. Cox; John D. Schreier


Archive | 2007

Bridged diazepan orexin receptor antagonists

Paul J. Coleman; Christopher D. Cox; Georgia B. McGaughey; Anthony J. Roecker; John D. Schreier


Archive | 2009

2,5-Disubstituted Morpholine Orexin REceptor Antagonists

Christopher D. Cox; Paul J. Coleman; Broc Flores; John D. Schreier


Archive | 2009

2,4-disubstituted pyrrolidine orexin receptor antagonists

Christopher D. Cox; Paul J. Coleman; John D. Schreier


Archive | 2006

Amidopropoxyphenyl Orexin Receptor Antagonists

Paul J. Coleman; John D. Schreier


Archive | 2009

2,5-disubstituted phenyl carboxamide orexin receptor antagonists

Jeffrey M. Bergman; Paul J. Coleman; Anthony J. Roecker; John D. Schreier


Archive | 2007

Amidoethylthioether orexin receptor antagonists

Paul J. Coleman; John D. Schreier


Archive | 2010

Amino tetrahydro-pyridopyrimidine pde10 inhibitors

Michael J. Breslin; Paul J. Coleman; Christopher D. Cox; Izzat T. Raheem; John D. Schreier

Collaboration


Dive into the John D. Schreier's collaboration.

Researchain Logo
Decentralizing Knowledge